ライフサイエンスコーパス: dengue

1 of vector-borne diseases such as malaria and dengue.

2 and/or less expensive diagnostic assays for dengue.

3 ere all independently associated with severe dengue.

4 biocontrol for arboviral diseases, including dengue.

5 ort, there is no effective treatment against dengue.

6 romoting/perpetuating inflammation in severe dengue.

7 r mechanisms of DHF and DSS in patients with dengue.

8 ruary, but peak timing was most variable for dengue.

9 es and their interplay with myeloid cells in dengue.

10 of therapeutics research and development for dengue.

11 We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is ass

12 r in vitro antibody dependent enhancement of Dengue-1, 2, 3 and 4 serotypes suggesting that pre-exist

13 Zika virus immune animals collected prior to Dengue-2 infection showed significant capacity for in vi

14 xpose Ae. aegypti mosquitoes to chikungunya, dengue-2 or Zika viruses, both individually and as doubl

15 virus leads to a significant enhancement of Dengue-2 viremia that is accompanied by neutropenia, lym

16 responses that significantly amplified after Dengue-2 virus infection.

17 rch trends have been shown to correlate with dengue activity.

18 ss-reactivity between different serotypes of dengue and also between a single-mutation and wild-type

19 less severe clinical manifestations, such as dengue and chikungunya infections, ZIKV infection likely

20 ellow fever, combined with the resurgence of dengue and chikungunya, constitute a wake-up call for go

21 In murine models of dengue and Ebola infection, sunitinib/erlotinib combinat

22 r, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and

23 stions about both the basic understanding of dengue and efforts to develop new tools.

24 future estimations of the economic burden of dengue and generate demand for additional routine admini

25 ence of the participation of HMGB1 in severe dengue and highlights novel considerations in the develo

26 The global burden of dengue and its geographic distribution have increased ov

27 found in the endothelial parameters between dengue and other febrile illness.

28 A fundamental mystery for dengue and other infectious pathogens is how observed pa

29 larity with other known flaviviruses such as dengue and West Nile viruses.

30 arthropod-borne infectious diseases such as dengue and yellow fever and emerging diseases such as Zi

31 s the continuing use of Wolbachia to control dengue and Zika virus transmission to humans.

32 ction with key human pathogens including the dengue and Zika viruses.

33 ypti, where it can block the transmission of dengue and Zika viruses.

34 II fusion proteins found in viruses such as dengue and Zika.

35 Current multiplexed diagnostics for Zika, dengue, and chikungunya viruses are situated outside the

36 ion of MAFB and SELENBP1 was common to ZIKV, dengue, and GBS infection; ATF5, TNFAIP3, and BAMB1 were

37 TF5, TNFAIP3, and BAMB1 were common to ZIKV, dengue, and WNF; and NAMPT and PMAlP1 were common to ZIK

38 s associated with maternal virus load, prior dengue antibodies, or abnormal pregnancy/infant outcomes

39 on with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derive

40 only identified epitopes unique to Zika and Dengue, but also identified epitopes unique to each Deng

41 g influenza, respiratory syncytial virus and dengue, but the generality of these signatures across al

42 Dengue can cause increased vascular permeability that ma

43 Drawing on the experience in managing dengue cases at the Queen Sirikit National Institute of

44 ta to simulate Aedes aegypti populations and dengue cases in 23 locations in the southeastern United

45 a, we show that in Bangkok, Thailand, 60% of dengue cases living <200 meters apart come from the same

46 Dengue, caused by four dengue virus serotypes (DENV-1 to

47 RMCE) system to Aedes aegypti, the vector of dengue, chikungunya, and Zika viruses.

48 ess among communities, potentially improving dengue control efforts.

49 engue-extracted tissues when compared to non-dengue controls.

50 Zika virus infection induced detectable Dengue cross-reactive serum IgG responses that significa

51 te, majorly serotype specific biosensors for dengue detection have been developed.

52 complexities and issues surrounding clinical dengue diagnosis and the laboratory diagnostic options c

53 n M) has greatly simplified laboratory-based dengue diagnosis.

54 on dengue, we discuss existing approaches to dengue diagnostics, disease prognosis, surveillance, and

55 , we observe protection from all symptomatic dengue disease at high antibody titers.

56 o approved therapeutics for the treatment of dengue disease despite the global prevalence of dengue v

57 rt in Nicaragua, we show that risk of severe dengue disease is highest within a narrow range of preex

58 ific mAb may be a therapeutic option against dengue disease.

59 Ninety patients with dengue during 2010-2012 in Singapore were prospectively

60 agement of children presenting with fever in dengue-endemic areas.

61 ions in nationally representative surveys in dengue-endemic countries.

62 ue virus coinfection should be considered in dengue-endemic countries.

63 ion and past DENV-2 infection in patients in dengue-endemic regions.

64 were recalled by immunization.IMPORTANCE The dengue epidemic presents a global public health challeng

65 e current knowledge and recent insights into dengue epidemiology, immunology, and pathogenesis, and t

66 Most patients with dengue experience mild disease, dengue fever (DF), while

67 increased expression of cytoplasmic HMGB1 in dengue-extracted tissues when compared to non-dengue con

68 atients with dengue experience mild disease, dengue fever (DF), while few develop the life-threatenin

69 mosquito-borne flaviviruses responsible for dengue fever and dengue hemorrhagic fever.

70 of dengue virus are the causative agents of dengue fever and dengue hemorrhagic fever.

71 h chorioretinal lesions reported in cases of Dengue fever and West Nile virus.

72 Zika virus as well as diagnostic testing for Dengue fever and West Nile virus.

73 negative ultrasound findings cannot rule out dengue fever due to the low sensitivity of this examinat

74 y, and splenomegaly are highly suggestive of dengue fever in clinically suspected cases.

75 pervasiveness of the infection, hemorrhagic dengue fever or dengue shock syndrome.

76 y of literature on the use of ultrasound for dengue fever screening; hence, the primary objective of

77 predictive value of ultrasound in diagnosing dengue fever were 58%, 84%, and 83%, respectively.

78 Dengue virus infection typically causes mild dengue fever, but, in severe cases, life-threatening den

79 engue virus (DENV) is the causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock

80 smission of the flaviviruses responsible for dengue fever, yellow fever, and chikungunya.

81 utility of ultrasound as a screening tool in dengue fever.

82 es showed that ZIKV infection most resembles dengue fever.

83 were positive and 95 cases were negative for dengue fever.

84 tection of non-structural protein 1 (NS1) of dengue fever.

85 l is a robust prognostic biomarker of severe dengue for adult and pediatric patients.

86 dengue infection than patients infected with dengue for the first time.

87 initiated on Jan 1, 2016, producing monthly dengue forecasts until November, 2016.

88 ever, but, in severe cases, life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome

89 le few develop the life-threatening diseases dengue hemorrhagic fever (DHF) or dengue shock syndrome

90 IgG) (RNNIg) is the greatest risk factor for dengue hemorrhagic fever (DHF) or dengue shock syndrome

91 ENV) is the causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome and

92 an important human pathogen responsible for dengue hemorrhagic fever, whose global incidence has inc

93 laviviruses responsible for dengue fever and dengue hemorrhagic fever.

94 are the causative agents of dengue fever and dengue hemorrhagic fever.

95 udy who were clinically diagnosed with a non-dengue illness ("C cases").

96 d with worse plasma leakage, occurs early in dengue illness and correlates with hypoargininemia and h

97 tion, we demonstrate that serum samples from dengue-immune pregnant women enhanced ZIKV infection.

98 Dengue immunoglobulin G (IgG) antibodies were measured a

99 s novel considerations in the development of dengue immunopathogenesis.

100 cases that had been incorrectly recorded as dengue in 2015 improved the prediction of the magnitude

101 mework for estimating the economic burden of dengue in any region, differentiated by four very differ

102 016, with a 90% chance of exceeding the mean dengue incidence for the previous 5 years.

103 improved the prediction of the magnitude of dengue incidence in 2016.

104 dictions correctly forecast an early peak in dengue incidence in March, 2016, with a 90% chance of ex

105 A total of 103 dengue-infected patients participated in the study.

106 f interleukin 1beta (IL-1beta) were lower in dengue-infected patients who had experienced a previous

107 In dengue-infected patients, elevated levels of syndecan-1

108 llenges remain in the clinical management of dengue-infected patients, especially in the absence of r

109 Symptomatic dengue infection during pregnancy almost doubled the odd

110 women who had livebirths were diagnosed with dengue infection during pregnancy.

111 lack of an appropriate small-animal model of dengue infection has greatly hindered the study of dengu

112 lack of an appropriate small-animal model of dengue infection has greatly increased the challenges in

113 nd therefore unable to distinguish Zika from Dengue infection in the absence of virus isolation.

114 Severe dengue infection increased the risk of fetal death by ab

115 Dengue infection is common, but little is known about it

116 cted patients who had experienced a previous dengue infection than patients infected with dengue for

117 rticularly in those experiencing a secondary dengue infection.

118 ika virus infection might enhance subsequent Dengue infection.

119 and can improve point-of-care diagnostics of dengue infection.

120 ve individuals from breakthrough or enhanced dengue infections suggest that poor T-cell immunity migh

121 Point estimates of apparent dengue infections vary widely, although the confidence i

122 genes were highly expressed in both ZIKV and dengue infections.

123 Dengue is a global public health problem and is caused b

124 Dengue is a mosquito-borne disease that threatens over h

125 Dengue is a RNA viral illness of the genus Flavivirus wh

126 Dengue is a significant global health problem.

127 Dengue is an acute febrile illness caused by dengue viru

128 Dengue is an important infectious disease that presents

129 erved data from San Juan, Puerto Rico, where dengue is endemic.

130 tion in Wolbachia-carrying cells, suggesting dengue is inhibited in Wolbachia-infected cells by local

131 The burden of dengue is large and growing.

132 Even though a vaccine against dengue is now available, which is a notable achievement,

133 Dengue is the most common arboviral infection of humans,

134 Dengue is the most common mosquito-borne viral disease i

135 Dengue is thus an example of an acute infection in which

136 ately associated with a mild or asymptomatic dengue-like disease, its appearance in the Americas has

137 hain CDRs.IMPORTANCE A chimeric yellow fever-dengue live-attenuated tetravalent vaccine is now being

138 asteur has developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD

139 nd specificity by using either live viruses (dengue, mumps, and measles viruses) or nucleic acid mate

140 Thus, immune correlates of severe dengue must be evaluated separately from correlates of p

141 clonal antibodies for rapid detection of the dengue nonstructural protein 1 (NS1).

142 reaks such as whooping cough in U.S. (2012), dengue outbreaks in India (2013) and China (2014).

143 ese results have implications for studies of dengue pathogenesis and for vaccine development, because

144 relevant small-animal model for the study of dengue pathogenesis and the development of dengue therap

145 tly increased the challenges in the study of dengue pathogenesis and the development of therapeutics.

146 infection has greatly hindered the study of dengue pathogenesis and the development of therapeutics.

147 ce, there are many knowledge gaps concerning dengue pathogenesis, especially with regards to the circ

148 Adult dengue patients admitted to the hospital on the third da

149 milar to the pathways found to be altered in dengue patients in previous metabolomics studies, indica

150 Considering dengue patients, the RHI was significantly lower for pat

151 clear cell (PBMC) and plasma samples from 77 dengue patients.

152 INTERPRETATION: This dengue prediction framework, which uses seasonal climate

153 abling novel interventions and approaches to dengue prevention and control.

154 ed on ZIKV immunoglobulin M and negative for dengue reactivity.

155 Among these, dengue-related Google search trends have been shown to c

156 spectives on key clinical lessons to improve dengue-related outcomes.

157 Dengue remains a significant public health problem, beca

158 The pathogenesis of severe dengue remains unclear, particularly the mechanisms unde

159 h 2-hydroxypropyl-beta-cyclodextrin restores dengue replication in Wolbachia-carrying cells, suggesti

160 recasts to predict the evolution of the 2016 dengue season in the city of Machala, following one of t

161 nd these chains quickly mix, and by the next dengue season viral lineages are no longer highly spatia

162 made at the start of the year for the entire dengue season.

163 yses that take into account baseline age and dengue serostatus.

164 but also identified epitopes unique to each Dengue serotype.

165 otentially enhance infection by heterologous Dengue serotypes.

166 reatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) occur.

167 es from patients within 24 hours of onset of dengue shock syndrome (DSS), and from healthy controls.

168 g diseases dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

169 factor for dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

170 dengue fever, dengue hemorrhagic fever, and dengue shock syndrome and is endemic to tropical and sub

171 f the infection, hemorrhagic dengue fever or dengue shock syndrome.

172 We demonstrate that dengue-specific antibodies enhance the infection of a pr

173 activated, but there was no accumulation of dengue-specific antibodies.

174 f dengue pathogenesis and the development of dengue therapeutics.

175 purposing approach has also been pursued for dengue therapy, with several compounds tested in clinica

176 currence of infectious diseases ranging from dengue to cholera.

177 U.S. locations would not sustain year-round dengue transmission according to our model.

178 on in many locations, projected increases in dengue transmission are limited to the southernmost loca

179 s based on current climate data suggest that dengue transmission at levels similar to those in San Ju

180 ed projected climate change-driven shifts in dengue transmission risk in this region.

181 bachia, the potential impact of Wolbachia on dengue transmission, and we discuss the remaining challe

182 ablished and exists on the current fringe of dengue transmission.

183 w fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is currently approved for

184 es elicited by a tetravalent live attenuated dengue vaccine and show that they resemble responses see

185 We developed a novel tetravalent dengue vaccine by using virus-like particles (VLPs), whi

186 A major challenge in dengue vaccine development is that cross-reactive anti-D

187 A dengue vaccine for individuals aged 9 years and older ha

188 Analyses of a clinically tested and licensed dengue vaccine that failed to protect seronegative indiv

189 Dengue vaccine trials have revealed deficits in our unde

190 pivotal phase III trials of the tetravalent dengue vaccine, CYD-TDV, and thereby enabled virus genot

191 etter evaluate the candidate live attenuated dengue vaccines.

192 In the southeastern United States, the dengue vector is widely established and exists on the cu

193 Dengue is an acute febrile illness caused by dengue virus (DENV) and a major cause of morbidity and m

194 gue disease despite the global prevalence of dengue virus (DENV) and its mosquito vectors.

195 pping geographical distribution of ZIKV with dengue virus (DENV) and other flaviviruses, possibly res

196 the world where other flaviviruses, such as dengue virus (DENV) and West Nile virus (WNV), are endem

197 vaccines for pathogenic flaviviruses such as dengue virus (DENV) and Zika virus.

198 Anti-Dengue virus (DENV) antibodies can be either protective

199 Although dengue virus (DENV) antibodies can neutralize or enhance

200 Zika virus (ZIKV) and dengue virus (DENV) are antigenically related flavivirus

201 pearance was not observable with a different dengue virus (DENV) as our control.

202 Dengue virus (DENV) causes 400 million infections annual

203 emerging virus that has recently spread into dengue virus (DENV) endemic regions and cross-reactive a

204 he last few decades, the global incidence of dengue virus (DENV) has increased dramatically, and it i

205 (DEP) chip was conducted to rapidly detect a dengue virus (DENV) in vitro based on the fluorescence i

206 inuing studies of vaccine approaches against dengue virus (DENV) infection are warranted, particularl

207 Dengue virus (DENV) infection in the presence of reactiv

208 results in areas with various levels of past dengue virus (DENV) infection incidence.

209 We sought to characterize dengue virus (DENV) infections among febrile children en

210 approaches to differentially detect ZIKV and dengue virus (DENV) infections, accentuating the urgent

211 Dengue virus (DENV) is a close family member of ZIKV and

212 Dengue virus (DENV) is a member of the genus Flavivirus

213 Dengue virus (DENV) is responsible for growing numbers o

214 Dengue virus (DENV) is the causative agent of dengue fev

215 ian cells, ZIKV, but not the closely related dengue virus (DENV) or West Nile virus (WNV), can effici

216 Robust dengue virus (DENV) replication requires lipophagy, a se

217 Transmission of dengue virus (DENV) requires successful completion of th

218 A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain l

219 public health problem and is caused by four dengue virus (DENV) serotypes (DENV1-4).

220 The four dengue virus (DENV) serotypes are mosquito-borne flavivi

221 d for detection of consensus DNA sequence of Dengue virus (DENV) using methylene blue (MB) as an inte

222 The cross-reactivity of ZIKV epitopes to dengue virus (DENV) was tested using IFN-gamma-ELISPOT a

223 athogens including yellow fever virus (YFV), dengue virus (DENV), and Zika virus (ZKV), all of which

224 antibodies that cross-react with the related dengue virus (DENV), we designed modified prM-E RNA enco

225 une responses protect against infection with dengue virus (DENV), yet cross-reactivity with distinct

226 ic tests, particularly for pregnant women in dengue virus (DENV)-endemic regions.

227 While it is widely accepted that dengue virus (DENV)-neutralizing antibody (nAb) titers a

228 e show that expression of ZIKV-NS2A, but not Dengue virus (DENV)-NS2A, leads to reduced proliferation

229 Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV

230 ZIKV viral RNA replication when compared to dengue virus (DENV).

231 ated individuals to infection by the related Dengue virus (DENV).

232 rotective immunity against pathogens such as dengue virus (DENV).

233 l inoculation of embryonic mouse brains with dengue virus 2 (DENV2), and found that DENV2 is sufficie

234 Nile virus, Japanese encephalitis virus, and dengue virus 2.

235 ible to ZIKV compared to the closely related dengue virus and induced the expression of alpha interfe

236 es are the limited assessment of the role of dengue virus and other possible cofactors, the small num

237 ed by Ae. aegypti include the 2 flaviviruses dengue virus and yellow fever virus and the alphavirus c

238 flaviviruses and neutralize a broad range of dengue virus and ZIKV isolates.

239 vaccination.IMPORTANCE The four serotypes of dengue virus are the causative agents of dengue fever an

240 f children with suspected ZIKV infection for dengue virus coinfection should be considered in dengue-

241 lectrochemical DNA hybridization sensors for Dengue virus detection, spanning both labeled and label-

242 opt a protein fold remarkably similar to the dengue virus E glycoprotein and related class II viral f

243 ordering effect of influenza virus, HIV, and Dengue virus FPs has been consistently observed.

244 ed sequences present in all the serotypes of Dengue virus has been employed for fabrication of a geno

245 Dengue virus has been shown to be particularly sensitive

246 ntibody to correlate with protection against dengue virus have highlighted the need for a human DENV

247 What was once blurred and confused with dengue virus in both diagnosis and name has since become

248 hat can provide long-term protection against dengue virus infection is needed.

249 Dengue virus infection typically causes mild dengue feve

250 Despite the clear medical importance of dengue virus infection, the mechanism of viral replicati

251 body titers in cases were unrelated to prior dengue virus infection.

252 tions such as tuberculosis, melioidosis, and dengue virus infection.

253 nd one sample each was confirmed for ZIKV or dengue virus infection.

254 derstanding of the innate immune response to dengue virus infection.

255 s for achieving long-term protection against dengue virus infection.IMPORTANCE Continuing studies of

256 Secondary dengue virus infections were also shown to influence dis

257 Dengue virus is an arthropod-borne virus transmitted pri

258 A as well as specific nucleotides.IMPORTANCE Dengue virus is an important human pathogen responsible

259 The process of RNA replication by dengue virus is still not completely understood despite

260 the search for an efficient vaccine against dengue virus is the immunodominance of the fusion loop e

261 utics that target this essential step of the dengue virus life cycle.

262 g of 8 of the 13 substrate cleavage sites by dengue virus NS2B/NS3 protease.

263 Dengue virus NS5 also binds SLAs from different serotype

264 We show that dengue virus NS5 binds SLA with a 1:1 stoichiometry and

265 Quantitatively characterizing dengue virus NS5-SLA interactions will facilitate the de

266 logous epitope located at the surface of the dengue virus particle.

267 ive analysis of the interactions between the dengue virus polymerase NS5 and SLA in solution has not

268 th sides of the active site as inhibitors of dengue virus protease.

269 th P bodies in uninfected cells and with the dengue virus replication complex after infection.

270 ion (UTR), is critical for the initiation of dengue virus replication, but quantitative analysis of t

271 Using a dengue virus serotype 2 (DENV-2) vaccine strain (PDK53),

272 Zika virus and dengue virus serotype 2 were isolated from a patient wit

273 s of the DENV3-specific 5J7 mAb epitope into dengue virus serotype 4 (DENV4).

274 rs and recipients, we assess the dynamics of dengue virus serotype 4 during the 2012 outbreak in Rio

275 operties of human antibodies that neutralize dengue virus serotype 4.

276 Dengue, caused by four dengue virus serotypes (DENV-1 to DENV-4), is a highly p

277 that is safe and effective against all four dengue virus serotypes (DENV-1-4) in recipients of all a

278 es on the envelope (E) protein of viruses of dengue virus serotypes 1, 2, and 3 targeted by human neu

279 rm protective efficacy against each of the 4 dengue virus serotypes remains to be definitively determ

280 thus far that causes disease in humans, from dengue virus to ZIKV, antagonizes the host type I interf

281 es aegypti, the latter an important Zika and Dengue virus vector insensitive to Ls Bin.

282 IMPORTANCE Dengue virus, a member of the family Flaviviridae, can r

283 OCK), to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype

284 d Bartonella), and 13 viruses (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps

285 travalent DLAV vaccine (TV005) with pools of dengue virus-derived predicted major histocompatibility

286 profile in monocytes isolated from ZIKV- and dengue virus-infected patients was comparable, except fo

287 n of robust correlates of protection against dengue virus.

288 esponses seen in humans naturally exposed to dengue virus.

289 is study defined the genetic epidemiology of dengue viruses (DENV) in two pivotal phase III trials of

290 For dengue viruses 1 to 4 (DENV1-4), a specific range of ant

291 d functional homologies between the Zika and Dengue viruses' envelope proteins raise the possibility

292 Because of the similarity of Zika and dengue viruses, an analogous unwanted outcome might occu

293 Despite antigenic similarities with dengue viruses, structural studies have suggested the ex

294 reduction neutralisation assays for Zika and dengue viruses.

295 Previous attempts of other groups to use dengue VLPs resulted in generally poor yields.

296 In this report, the third in a Series on dengue, we discuss existing approaches to dengue diagnos

297 tted viruses, such as those that cause Zika, dengue, West Nile encephalitis, and chikungunya, have be

298 of mosquito-transmitted flaviviruses include dengue, yellow fever and Zika viruses.

299 tropical regions, is the principal vector of dengue, yellow fever, Zika and Chikungunya viruses.

300 Outbreaks caused by Dengue, Zika and Chikungunya viruses can spread rapidly